Post-treatment Serum Autotaxin and Subsequent Hepatocellular Carcinoma Development During Nucleos(t)ide Analog Therapy for Chronic Hepatitis B: An Exploratory Study

Objective The risk of hepatocellular carcinoma (HCC) persists despite nucleos(t)ide analog (NA) therapy in patients with hepatitis B virus (HBV) infection. We investigated whether post-treatment serum autotaxin (ATX), a noninvasive fibrosis-related biomarker, is associated with subsequent HCC development during NA therapy.Methods We measured the serum ATX levels at baseline and at week 48 of NA therapy. Patients were followed for HCC development. The optimal ATX cutoff value was determined using a receiver operating characteristic (ROC) curve analysis, and cumulative HCC incidence was evaluated using the Kaplan-Meier method.Patients This retrospective single-center cohort study included 67 treatment-naïve patients with chronic hepatitis B who received NA therapy for at least 48 weeks.Results The median age was 59 years, and 58.2% of the patients were men. During a median follow-up period of 6.3 years, five patients developed HCC. The serum ATX levels decreased significantly after 48 weeks of NA therapy (0.93 vs. 0.84 mg/L, P < 0.001). Patients who subsequently developed HCC had significantly higher post-treatment ATX levels than those who did not (1.32 vs. 0.84 mg/L, P = 0.010). Among the evaluated fibrosis-related biomarkers, ATX showed the highest discriminative ability for HCC development, with an area under the receiver operating characteristic curve of 0.90. With an ATX/upper limit of normal ratio cutoff of 0.92, patients with elevated ATX levels that showed a significantly higher cumulative incidence of HCC than those with lower levels (10-year incidence: 25.0% vs. 1.96%, log-rank P = 0.001).Conclusions The serum ATX levels decreased after NA therapy, but remained elevated in patients who subsequently developed HCC. Validation of these preliminary findings in larger prospective cohorts is needed.

Authors

Institutions

Publication Details

Journal
Internal Medicine
Published
2026-11-19
DOI
https://doi.org/10.2169/internalmedicine.8073-26
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Post-treatment Serum Autotaxin and Subsequent Hepatocellular Carcinoma Development During Nucleos(t)ide Analog Therapy for Chronic Hepatitis B: An Exploratory Study

浩二 五十嵐, Shun‐ichi Wakabayashi, Taiki Okumura, Tomoo Yamazaki et al.
Internal Medicine
Hepatitis B Virus Studies
article

Post-treatment Serum Autotaxin and Subsequent Hepatocellular Carcinoma Development During Nucleos(t)ide Analog Therapy for Chronic Hepatitis B: An Exploratory Study

浩二 五十嵐, Shun‐ichi Wakabayashi, Taiki Okumura, Tomoo Yamazaki, Takefumi Kimura, Naoki Tanaka, Kaede Fujita, Satoshi Shimamoto, Yuma Kamijo, Takanobu Iwadare, Hiroaki Sekita, Hiroyuki Kobayashi
article en

Abstract

Objective The risk of hepatocellular carcinoma (HCC) persists despite nucleos(t)ide analog (NA) therapy in patients with hepatitis B virus (HBV) infection. We investigated whether post-treatment serum autotaxin (ATX), a noninvasive fibrosis-related biomarker, is associated with subsequent HCC development during NA therapy.Methods We measured the serum ATX levels at baseline and at week 48 of NA therapy. Patients were followed for HCC development. The optimal ATX cutoff value was determined using a receiver operating characteristic (ROC) curve analysis, and cumulative HCC incidence was evaluated using the Kaplan-Meier method.Patients This retrospective single-center cohort study included 67 treatment-naïve patients with chronic hepatitis B who received NA therapy for at least 48 weeks.Results The median age was 59 years, and 58.2% of the patients were men. During a median follow-up period of 6.3 years, five patients developed HCC. The serum ATX levels decreased significantly after 48 weeks of NA therapy (0.93 vs. 0.84 mg/L, P < 0.001). Patients who subsequently developed HCC had significantly higher post-treatment ATX levels than those who did not (1.32 vs. 0.84 mg/L, P = 0.010). Among the evaluated fibrosis-related biomarkers, ATX showed the highest discriminative ability for HCC development, with an area under the receiver operating characteristic curve of 0.90. With an ATX/upper limit of normal ratio cutoff of 0.92, patients with elevated ATX levels that showed a significantly higher cumulative incidence of HCC than those with lower levels (10-year incidence: 25.0% vs. 1.96%, log-rank P = 0.001).Conclusions The serum ATX levels decreased after NA therapy, but remained elevated in patients who subsequently developed HCC. Validation of these preliminary findings in larger prospective cohorts is needed.

Internal Medicine
Shinshu University (JP), Shinshu University Hospital (JP), Tosoh (Japan) (JP)
Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science
Good health and well-being
Hepatitis B Virus Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon